March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. Photo via Getty Images

An emerging biotech company in Houston has closed its series A with outsized success.

March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. The company has now raised more than $51 million in total.

Last year, March Biosciences announced its strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience. CEO Sarah Hein met her co-founder, Max Mamonkin, at the TMC Accelerator for Cancer Therapeutics. Along with fellow co-founder Malcolm Brenner, March Biosciences launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital). Its goal is to fight cancers that have been unresponsive to existing immunotherapies using its lead asset, MB-105.

An autologous CD5-targeted CAR-T cell therapy, MB-105 is currently in phase-1 trials in patients with refractory T-cell lymphoma and leukemia. The treatment is showing signs of being both safe and effective, meriting a phase-2 trial that will begin early next year. The funds raised from the series A will help to finance the Phase 2 clinical development of MB-105 to expand on the existing data with optimized manufacturing processes.

“This oversubscribed financing enables us to advance our first-in-class CAR-T therapy, MB-105, into a Phase 2 trial for T-cell lymphoma – an indication with an exceptionally poor prognosis and few treatment options,” says Hein. “With the support and confidence of our investors, we are not only advancing our lead program but also expanding our pipeline, underscoring our commitment to delivering best-in-class therapies to patients that can change the treatment paradigm for these challenging cancers.”

But that’s not the only exciting news that Hein and her associates have to report. March Biosciences has recently partnered with cell therapy venture studio, Volnay Therapeutics. Led by highly experienced cell therapy development veterans, the March Biosciences team will work to develop a scalable manufacturing process for MB-105 that will lead to commercialization. Volnay co-founder and CEO Stefan Wildt, who held key R&D leadership positions in cell and gene therapy units at Novartis and Takeda, has also joined the board of March Biosciences. The board of directors is also welcoming Cassidy Blundell of Mission BioCapital and Owen Smith of 4BIO Capital.

“The team at March Biosciences is leveraging powerful science and promising clinical data to tackle cancers with significant unmet need,” says Blundell, a partner at Mission BioCapital. “We're excited to support their journey and believe their focused approach with MB-105 could lead to significant breakthroughs in the CAR-T space.”

The Houston-born company, which is a finalist for the 2024 Houston Innovation Awards, continues to accelerate quickly, in part thanks to its home base. After all, existing local investors like TMC Venture Fund also participated in the new raise. As Hein said last year, “Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

Diakonos Oncology Corp. closed its seed round to the tune of $11.4 million. Photo via Getty Images

Houston oncology therapeutics co. raises $11.4M in seed funding

money moves

A Houston-based, clinical-stage immuno-oncology company has raised an oversubscribed round of seed funding.

Diakonos Oncology Corp. closed its seed round to the tune of $11.4 million. The funding will go toward supporting the company's Phase 2 trial — slated for later this year, following its ongoing Phase 1 study — and operations through late next year. California-based biotechnology investment firm Restem Group Inc. led the round, and existing investors contributed as well.

“We greatly appreciate the support of these investors in sharing our passion for improving the lives of patients suffering from deadly cancers such as glioblastoma,” Mike Wicks, Diakonos CEO, says in a news release. “The fact that this financing is nearly triple our initial target also shows they share our confidence in the effectiveness of our unique cancer therapy.”

Founded in 2016, the company recently received FDA Fast Track designation for its dendritic cell vaccine, DOC1021, which targets glioblastoma multiforme, or GBM, the most common and most lethal malignant brain tumor in adults. Diakonos also received the designation for its pancreatic cancer treatment.

"We are thrilled to invest in this groundbreaking company that is at the forefront of cancer treatment innovation. As a firm deeply involved in the cell therapeutic field, we recognize the immense potential of their pioneering work with dendritic cell therapies and we are confident that this can become a new standard of care for cancer in the future," adds Andres Isaias, executive chairman of Restem Group Inc.

Diakonos Oncology's DOC1021 uses the body’s natural anti-viral immune response to fight GBM. The vaccine mimics viral infection with the patient’s cancer markers. Essentially, DOC1021 uses the body’s own natural ability to detect and eliminate infected cells. According to the company, all of the patients who have tried the treatment have exceeded survival expectations. And DOC1021 appears to be extremely safe, with no serious adverse effects having been reported.

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort.

TMC names 2024 cohort of cancer treatment innovators

ready to grow

For the fourth year, Texas Medical Center Innovation has named its annual cohort of Texas health tech innovators working on promising cancer therapeutics.

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort last week, and the 23 Texas researchers and companies selected will undergo a nine-month program that will provide them with mentorship and programming, as well as open doors to potential investors and strategic partners.

“The ACT program provides a bridge to commercialization in Texas by surrounding innovators with strategic mentorship, milestone development, and a network of resources to move their projects forward,” Emily Reiser, associate director of TMC Innovation, says in a news release. "We are excited to welcome this year's cohort and to continue enabling participants to advance their solutions to treat cancer."

The program has accelerated 76 researchers and companies to date, many of which — like March Biosciences and Mongoose Bio — have gone on to secure $130 million in funding from venture capitalists and grant funding.

“Our program has cultivated a dynamic ecosystem where partners, researchers, and inventors, who have been part of the journey since its inception and received various forms of funding, continue to propel their life-saving products and technologies forward," Ahmed AlRawi, program manager of ACT, says in the release. "Our 2024 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. Additionally, we are particularly proud that the cohort includes a blend of new and recurring organizations that have leveraged this opportunity in the past to extend their work and continue the momentum to build off the successes of our previous years.”

The 2024 participants are:

  • Alexandre Reuben of UT-MD Anderson Cancer Center
  • Betty Kim & Jiang Wen of UT-MD Anderson Cancer Center
  • Bin He of Houston Methodist
  • Daniel Kiss & John Cooke of PeakRNA at Houston Methodist
  • Hongjun Liang of Texas Tech-Lubbock
  • Jacob Goell & Isaac Hilton of Mercator Biosciences at Rice University
  • Jay Hartenbach & Matthew Halpert of Diakonos Oncology Corp.
  • Kathryn O’Donnell of UT-Southwestern
  • Maralice Conacci Sorrell of UT-Southwestern
  • Neeraj Saini of UT-MD Anderson Cancer Center
  • Neil Thapar of Barricade Therapeutics Corp.
  • Nina Keshavarzi of Celine Biotechnologies
  • Raphael G. Ognar & Henri Bayle of NKILT Therapeutics Inc.
  • Richard Austin & Michael Abrahamson of Reglagene Inc.
  • Tim Peterson & Joppe Nieuwenhuis of Bioio Inc.
  • Todd Aguilera & Eslam Elghonaimy of UT-Southwestern
  • Venkata Lokesh Battula of Siddhi Therapeutics Inc. at UT-MD Anderson Cancer Center
  • Weei-Chin Lin & Fang-Tsyr Lin of Baylor College of Medicine
  • Yong Li & Dongxiao Feng of Sotla Therapeutics at Baylor College of Medicine
  • Anil Sood & Zhiqiang An of UT-MD Anderson Cancer Center
  • Narendra Kumar & Jayshree Mishra of Texas A&M-College Station
  • Tao Wang of NightStar Biotechnologies Inc. at UT-Southwestern
  • Jian Hu of UT-MD Anderson Cancer Center
The Texas Medical Center Innovation Factory has named the 16 companies making up the inaugural cohort in the Innovate UK Global Incubator Programme. Photo via tmc.edu

TMC names inaugural cohort for unique accelerator with UK

coming to HOU

Sixteen digital health and medical device startups founded in the United Kingdom have been selected for a customized accelerator at the Texas Medical Center's Innovation Factory.

In partnership with Innovate UK, TMCi created the Innovate UK Global Incubator Programme, a new accelerator that supports UK businesses as they build their United States go-to-market plan. The program builds the BioBridge relationship between TMC and the UK that was originally established five years ago.

“The TMC UK BioBridge program was launched with the UK Department for Business and Trade in 2018 to serve as a gateway for advancing life sciences and foster innovation and research between our two countries," says Ashley McPhail, chief external affairs and administration officer for TMC, in a news release. "We saw an opportunity to work with Innovate UK to develop a larger program with the UK after the success of the 11 companies that previously participated in our health tech accelerator."

The 16 companies will participate in the program from June to November. The cohort is expected to arrive in Houston on June 5 and have access to TMCi's facilities, network of mentors and potential clients, funding, potential customers, and curated programing — all while being a unique entry point into the US. The new offering joins three other globally recognized curriculums: Biodesign, Accelerator for Cancer Therapeutics, and Health Tech.

“TMCi nurtures long-term growth, development, and competitiveness to increase startups chances of success and global expansion," says Emily Reiser, associate director of TMC Innovation. "By bringing their novel technologies and exposing them to a curated selection of TMC’s expert network, startups receive support and evaluation to build, scale, and expand in the US market."

Two of the cohort's specialties include cardiovascular and oncology — two of TMC's strongest areas of expertise — with solutions ranging from surgical devices to AI-enabled risk stratification and hospital efficiency.

Innovate UK is the country's national innovation agency dedicated to supporting business-led innovation in all sectors.

“The United Kingdom is fully committed to improving global healthcare through scientific collaboration," says His Majesty’s Consul General in Texas Richard Hyde in the release. "Through the expansion of the TMC UK BioBridge and in partnership with Innovate UK, this programme will help to expose the brightest and best British companies to the world’s largest medical city. Our companies will collaborate and grow as they work to develop cutting edge technology. The partnership between the UK Government and TMC demonstrates that international collaboration can drive both economic growth and improvement to quality of life.”

The 16 companies making up the inaugural cohort are as follows, according to TMC.

  • AINOSTICS aims to revolutionize the treatment and prevention of neurological conditions, such as dementia, by developing innovative AI-enabled solutions that draw novel insights from routinely acquired non-invasive medical scans to deliver accurate diagnosis and outcome prediction, and in turn facilitate personalized care and timely access to disease-modifying treatments for patients.
  • Alvie is a blended human plus AI-enabled digital solution providing personalised pre and rehabilitation coaching and supportive care for cancer and surgery. Alvie's technology combines data profiling, risk-stratification and tailored prescriptions of health and well-being with curated educational content, targeted behaviour change coaching and expert support through chat messaging and virtual consultations.
  • C the Signs™ is a validated AI cancer prediction platform, which can identify patients at risk of cancer at the earliest and most curable stage of the disease. Used by healthcare professionals, C the Signs can identify which tumor type a patient is at risk of and recommend the most appropriate next step in less than 30 seconds. The platform has detected over 10,000 patients with cancer, with over 50 different types of cancer diagnosed, and with a sensitivity of >98% for cancer.
  • At PEP Health, We believe all patients deserve the best care possible. Our cutting-edge machine-learning technology enables healthcare organisations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
  • PreciousMD improves the lives of lung-cancer and other lung-related illnesses patients worldwide by enabling imaging-based diagnostics needed for personalized treatment pathways.
  • Ufonia is an autonomous telemedicine company, we use large language models and voice AI to increase the capacity of clinical professionals.
  • My mhealth offers digital therapeutics for a range of long-term conditions- COPD, Asthma, Diabetes and Heart Disease. Our product has been successfully deployed in the UK and India, with >100,000 users registered to date. Our solutions empower patients to self-manage their conditions, resulting in dramatic improvements in outcomes, as evidenced through multiple clinical trials and real-world evaluations.
  • At Surgery Hero, we offer a clinically backed solution that ensures whole-human support before and after surgery. We help health systems, employers and health plans cut costs without sacrificing quality of care.
  • Panakeia's software platform enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images without needing wet lab assays.
  • QV Bioelectronics are striving to deliver longer, better quality lives for brain tumour patients. Using their first-of-its-kind implantable electric field therapy device, GRACE, QV will provide effective, focal & continuous treatment without impacting patient quality of life.
  • 52 North is a med-tech company focused on improving health outcomes and health equity by reinventing care pathways. The NeutroCheck® solution is a finger-prick blood test and digital platform built to significantly improve safety and quality of life for cancer patients, by helping to identify at-home those patients who are at risk of the most fatal side-effect of chemotherapy: neutropenic sepsis.
  • Somnus is fulfilling an unmet need in global healthcare by developing real-time, point of care blood propofol monitoring. Its products will improve the care of sedated and anaesthetised patients, save money for hospitals, and facilitate a major reduction in greenhouse gas emissions.
  • ScubaTx is a breakthrough organ transplant preservation company established to solve the global unmet need for cost-efficient and longer-duration organ preservation technology. ScubaTx has developed a simple, small and affordable device which uses Persufflation to extend the preservation of organs.
  • IBEX is on a mission to help people live active, healthy and productive lives by increasing their access to early diagnosis of osteoporosis. The IBEX BH software as medical device delvers routine, automated assessment of fracture risk from routine radiology for earlier detection and more equitable treatment of osteoporosis.
  • NuVision produces products derived from donated human amniotic membrane that are used in ophthalmology to help patients with chronic, traumatic and post-surgical wounds of the eye to be treated earlier and recover more fully and more quickly. The company’s products are also used in the management of dry eye disease, a debilitating conditions that affects around 17m people in the USA.
  • Calon Cardio-Technology is on a mission to improve quality of life for patients with Left Ventricular Assist devices (LVAD) and reduce the common post operative complications associated with these implantable heart pumps. We plan to do this by introducing a completely wireless heart pump system and augment patient follow-up with built-in remote monitoring capabilities.
This month, TMCi is welcoming a slew of health tech and cancer innovators who will advance solutions in medicine over the next several months. Image via TMC.edu

TMC announces entrepreneurs, researchers joining its 2 health tech accelerators

coming soon

The Texas Medical Center has announced the latest cohorts of its two health tech accelerators.

The Texas Medical Center Innovation has named eight companies that are in the Spring 2023 Accelerator for HealthTech cohort. TMCi also announced 21 participants are set to join the 2023 Accelerator for Cancer Therapeutics cohort. Both programs connect the entrepreneurs and innovators to experts at TMC’s campuses to solve unmet clinical needs and reach the next business milestone.

“At TMC Innovation, we start with a promise of uniting cutting-edge innovators in science and medicine with the talent found at the Texas Medical Center," says Emily Reiser, associate director of TMC Innovation, in a news release. "Our 2023 cohort members are tackling some of the most critical issues we face today in healthcare.

"We are excited to welcome a new group of researchers and companies to the TMC Innovation Factory, and to work collaboratively with our new cohort members and our partners from across the Texas Medical Center," she continues.

Here's what 2023 can expect from these two program's cohorts.

TMCi HealthTech Accelerator

The six-month, twice annual HealthTech Accelerator — originally launched in 2014 with over 225 alumni companies — focuses on digital health and medical device startups. The spring cohort are addressing solutions across maternal medicine, mental health, diagnostics, patient experience, and artificial intelligence.

"Uniting talented professionals from across the globe provides a unique opportunity for innovation, creativity, and development in diverse areas of expertise," says Devin Dunn, head of the Accelerator for Healthtech at TMCi, in the release. "Our tailored program maximizes participants' experiences while determining the best match between these companies and Texas Medical Center’s network."

The cohort was selected following a November bootcamp that introduced potential startup members to the TMC and the Houston health care community.

The following companies will join the TMC this month:

  • Based in Roseville, Minneapolis, Bloom Standard is deploying the first self-driving pediatric ultrasound to earlier diagnose heart and lung conditions in primary care, remote and under-resourced settings.
  • San Francisco-based Ejenta automates remote monitoring and care using AI technology exclusively licensed from NASA. “Intelligent agents” learn from connected devices, claims and EMR data to monitor patients, predict health and to provide automated support for patients and automated workflow for clinicians.
  • Kintsugi, based in Berkley, California, is on a mission to see mental health more clearly by developing novel voice biomarker infrastructure to detect signs of depression and anxiety from short clips of free-form speech.
  • San Francisco-based Lana Health is modernizing patient experiences, across the care continuum with an end-to-end, scalable platform, enabling frictionless care transitions, high patient satisfaction, and better clinical outcomes.
  • Liberate Medical, from Crestwood, Kentucky, improves outcomes for mechanically ventilated patients using its breakthrough, non-invasive, respiratory muscle-protective, neurostimulation device, VentFree.
  • Limbix, headquartered in Palo Alto, has a mission to improve mental health with accessible technology.
  • Nua Surgical, from Galway, Ireland, Nua Surgical is an award-winning Irish start-up dedicated to innovating in women’s health.
  • Houston-based Prana Thoracic is developing solutions for the detection and intervention of early-stage lung cancer.

Accelerator for Cancer Therapeutics

The TMC has announced the 21 researchers and companies tapped to join the 2023 Accelerator for Cancer Therapeutics.

The nine-month program, funded by the Cancer Prevention and Research Institute of Texas in partnership with the Gulf Coast Consortia and the University of Texas Medical Branch, supports investigators and early-stage biotechnology companies with innovative solutions in cancer therapeutics. Participants will be mentored by a group of scientific, business, and innovation leaders to ultimately be positioned to apply for grants and pitch to investors and corporate partners to further the development of their innovative cancer solutions.

“For this third cohort, we focused on a strategic and extensive recruitment process, including the evaluation of 1,679 cancer research projects. From 56 applications, we selected 21 participants that will gain access to valuable resources, integrated training and mentorship to prepare for clinical trials,” says Ahmed AlRawi, program manager of Accelerator for Cancer Therapeutics, in the release. “Our 2023 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. We are excited to continue the momentum and build off the successes of our previous years.”

Forty-five participants have gone through the accelerator program since its launch in 2021, and collectively, the entrepreneurs have raised more than $90 million in funding and three projects are in the clinic.

The 2023 cohort participants are focused on a wide range of therapeutic assets, including small molecule, antibody, peptide/protein, cell therapy, and other. The 2023 cohort kicks off their nine-month program in January.

The participants include:

  1. Dr. Amit K. Tripathi – UNT-Health Science Center
  2. Dr. Darshan Gandhi (ImproveBio, LLC)
  3. Dr. Frank McKeon (Tract Pharmaceutical) – University of Houston
  4. Dr. Hemanta Baruah (Aakha Biologics)
  5. Dr. Joshua Gruber – UT-Southwestern
  6. Dr. Kyoji Tsuchikama – UT Health Science Center-Houston
  7. Dr. Maralice Conacci Sorrell – UT-Southwestern
  8. Dr. Michael Buszczak – UT-Southwestern
  9. Dr. Nadezhda (Nadia) German -Texas Tech-Lubbock
  10. Dr. Parsa Modareszadeh (HemePro Therapeutics) – UT-Dallas
  11. Dr. Robert Kruse (HydroGene Therapeutics)
  12. Dr. Xiang Zhang – Baylor College of Medicine
  13. Dr. Youngwook Won (Singular Immune, Inc.)
  14. Dr. Zhi-Ping Liu (Raphael Pharmaceutical LLC) – UT-Southwestern
  15. Dr. Jonathan Arambula (InnovoTEX Inc.)
  16. Dr. Isaac Chan – UT-Southwestern
  17. Dr. Olga Granaturova (Ruptakine Inc.) – UT Health Science Center-Houston
  18. Dr. Jim Song (Tranquility Biodesign) – Texas A&M-College Station
  19. Dr. Rosa Selenia Guerra-Resendez (Quetzal Bio, LLC) – Rice University
  20. Dr. Cassian Yee (Mongoose Bio, LLC) – UT-MD Anderson Cancer Center
  21. Dr. Manjeet Rao (Niragen, Inc.) – UT Health Science Center-San Antonio


A UH professor is fighting cancer with a newly created virus that targets the bad cells and leaves the good ones alone. Photo via Getty Images

University of Houston researchers snag $1.8M to develop cancer-fighting virus

immunotherapy innovation

Viruses attack human cells, and that's usually a bad thing — some Houston researchers have received fresh funding to develop and use the evil powers of viruses for good.

The developing cancer treatment is called oncolytic virotherapy and has risen in popularity among immunotherapy research. The viruses can kill cancer cells while being ineffective to surrounding cells and tissue. Basically, the virus targets the bad guys by "activating an antitumor immune response made of immune cells such as natural killer (NK) cells," according to a news release from the University of Houston.

However exciting this rising OV treatment seems, the early stage development is far from perfect. Shaun Zhang, director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston, is hoping his work will help improve OV treatment and make it more effective.

“We have developed a novel strategy that not only can prevent NK cells from clearing the administered oncolytic virus, but also goes one step further by guiding them to attack tumor cells. We took an entirely different approach to create this oncolytic virotherapy by deleting a region of the gene which has been shown to activate the signaling pathway that enables the virus to replicate in normal cells,” Zhang says in the release.

Zhang, who is also a M.D. Anderson professor in the Department of Biology & Biochemistry, has received a $1.8 million grant from the National Institutes of Health to continue his work.

Zhang and his team are specifically creating a new OV — called FusOn-H2 and based on the Herpes simplex 2 virus.

“Our recent studies showed that arming FusOn-H2 with a chimeric NK engager (C-NK-E) that can engage the infiltrated natural killer cells with tumor cells could significantly enhance the effectiveness of this virotherapy,” he says. “Most importantly, we observed that tumor destruction by the joint effect of the direct oncolysis and the engaged NK cells led to a measurable elicitation of neoantigen-specific antitumor immunity.”

Shaun Zhang is the director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston and M.D. Anderson professor in the Department of Biology & Biochemistry. Image via UH.edu

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

10+ can't-miss Houston business and innovation events for November

WHERE TO BE

From networking meetups to pitch competitions, November is filled with opportunities for Houston innovators. Here's a roundup of events you won't want to miss out on so mark your calendars and register accordingly.

Note: This post might be updated to add more events.

Featured event: November 14 — Houston Innovation Awards

Celebrate Houston innovation at InnovationMap's 2024 Houston Innovation Awards on November 14 at TMC Helix Park. Click here to read about the finalists. Secure your tickets below.


November 4 - 5 — In-Space Physical AI Workshop

The Rice University Office of Innovation, in partnership with NASA, Purdue University and the Ion District, will host the In-Space Physical AI Workshop. The event will bring together industry leaders, startups, government agencies and researchers to explore the cutting edge of AI in space exploration. Workshop sessions will cover a range of topics in physical AI ⎯ robots or systems that apply AI to autonomously sense, interact with and adapt to their environment using complex computational, sensory and motor abilities to perform challenging real-world tasks.

This event begins Monday, November 4, from 8 am to 8:30 pm at the Ion. Click here to register.

November 6 — Waste to Work: Transforming Waste into Valuable Resources

This event will delve into innovative strategies and technologies that transform waste materials into valuable resources, driving sustainability and economic growth. Topics will include innovative technologies in waste conversion, policy and regulation, economic opportunities in waste management, success stories from around the world, and trends and predictions.

This event is Wednesday, November 6, from 3 to 6 pm at the Cooley University Life Center at UTHealth Houston. Click here to register.

November 7 — Bots & Brews

This event is the fall meetup for the H-town robotics, drones, geospatial, data & AI crowd, hosted by the Energy Drone & Robotics Coalition. Leaders from energy/engineering asset owner/operators, service companies, tech solution providers, startups & investors in the energy and industrial robotics/drone/data & AI community come together to catch up and talk about real-world solutions, projects and deployments.

The event is Thursday, November 7, from 5:30 to 7:45 at The Cannon West. Click here to register.

November 8 — Tech Fest Live

The UH Technology Bridge will be buzzing with students, industry leaders, innovators, and tech enthusiasts as they come together to celebrate the future of technology and innovation. There will be exciting panel discussions, interactive exhibits, and networking opportunities in the fields of digital media, energy, AI and entrepreneurship.

This event is Friday, November 8, from 8 am to 4 pm at UH Technology Bridge. Click here to register.

November 12 — The New Majority Summit

1863 Ventures, a D.C.-based accelerator and venture capital firm, is focused on advancing New Majority entrepreneurs—those historically marginalized or underrepresented—towards greater wealth and success. This immersive program centers on the essential skills and insights needed to transition into becoming an effective CEO.

Throughout the event, registrants will delve into key topics, including the entrepreneurial mindset, understanding one's customer base, establishing scalable processes, financial management strategies, and effective fundraising techniques. Prepare to be inspired and empowered after hearing from 1863 CEO Melissa Bradley, founder & CEO of LAMIK Beauty Kim Roxie, co-founder of Donna's Recipe Gina Woods and more.

This event is Tuesday, November 12, from 8:30 am to 5 pm at the Ensemble Theatre. Click here to register.

November 12 — Software Day at the Ion: Blockchain 2.0: Innovating Across Industries

Software Day is a monthly series driving the support, inspiration, and connections needed to help startups on their path to rapid, sustainable growth. Each month, software day will include office hours (by application), a keynote session, and networking. This software day is moderated by Samantha Lewis, partner at Mercury. Panelists include the former CEO of BBVA Compass, Manolo Sanchez and Ian Epstein, co-CEO ProfitR, global head of capital markets and distribution at republic.

This event is Tuesday, November 12, from 3:30 to 7 pm at the Ion. Click here to register.

November 13 — Envision 2024

Learn how companies in the ecosystem of the largest medical center in the world are addressing challenges head-on, meet some of our entrepreneurs, and network. This event is presented in partnership with Innovate UK and BioInnovation Institute.

This event is Wednesday, November 13, from 1 to 5 pm at TMC Innovation Factory. Click here to register.

November 14 — State of the Texas Medical Center

The Greater Houston Partnership's State of the Texas Medical Center returns. William F. McKeon, President and CEO of the Texas Medical Center, will deliver an annual address, discussing the tremendous progress in discovery and life sciences at the world's largest medical center. New to this year's State of the Texas Medical Center, is a dynamic pitch competition, the TMC Innovation Pitch Tank.

This event is Thursday, November 14, from 11 am to 1:30 pm at Hilton Americas. Click here to register.

November 15 — 2024 ERG Symposium

This event, hosted by Houston Methodist, will include a keynote from Shona Pinnock, VP of DEI for Peloton as well as insights from other local organizations such as HESS, Houston Methodist, TDECU, Greystone and more. These experts will share how ERGS are impacting business goals, enhancing company culture and employee engagement and will provide valuable insights and actionable takeaways to help organizations maximize the effectiveness of ERGs.

This event is Friday, November 15, from 9 am to 1 pm at The Westin Houston Medical Center. Click here to register.

November 19 — A Texas Talk: Reflecting on the Past, Envisioning the Future

Center for Houston’s Future’s signature fall event, Dinner and Conversation presented by Harvey-Cleary, will feature an exciting conversation between two important Texas voices. Stephen Harrigan, the award-winning author of 12 fiction and non-fiction books, will appear in conversation with Sonal Shah, CEO of the Texas Tribune, who has a long record of social impact work across multiple sectors.

This event is Tuesday, November 19, from 6 to 9 pm at the River Oaks Country Club. Click here to register.

November 21 — Visionary Voices: A Fireside Chat with Dan Ammann, President of ExxonMobil Low Carbon Solutions

In this fireside chat, Dan Ammann, president of ExxonMobil Low Carbon Solutions, will discuss ExxonMobil’s plans in advancing a thoughtful energy transition by delivering the critical energy and products the world needs and reducing their own and others’ greenhouse gas emissions. He’ll talk about Low Carbon Solutions’ transformative projects and investments aimed at bringing lower-emission technologies like hydrogen, lithium, and carbon capture and storage to market, making them accessible to carbon-intensive industries worldwide.

This event is Thursday, November 21, from 8 to 10 am at the Ion. Click here to register.

Overheard: Houston's top energy transition founders explain their biggest challenges

Houston Innovation Awards

From finding funding to navigating the pace of traditional oil and gas company tech adoption, energy transition companies face their fair share of challenges.

This year's Houston Innovation Awards finalists in the Energy Transition category explained what their biggest challenge has been and how they've overcome it. See what they said below, and make sure to secure your tickets to the Nov. 14 event to see which of these finalists win the award.

"The evolving nature of the energy industry presents opportunities to solve some of our industry's greatest challenges. At Amperon we help optimize grid reliability and stability with the power of AI demand forecasting."

Sean Kelly, CEO of Amperon, an AI platform powering the smart grid of the future

"The biggest challenge in leading an energy transition-focused startup has been balancing the urgency for sustainable solutions with the slow pace of change in traditional industries like oil and gas. Many companies are cautious about adopting new technologies, especially when it comes to integrating sustainability initiatives. We overcame this by positioning our solutions not just as environmentally friendly, but as tools that improve safety, efficiency, and cost savings. By aligning our value proposition with their operational goals and demonstrating real, measurable benefits, we were able to gain traction and drive adoption in industries that are traditionally resistant to change."

— Dianna Liu, CEO of ARIXTechnologies, an integrated robotics and data analytics company that delivers inspection services through its robotics platforms

"Scaling up production of hard tech is a major challenge. Thankfully, we recruited top-notch talent with experience in technology scale-up and chemical processes. In addition, we've begun building partnerships with some of the world's largest chemical manufacturers in our space who are excited to be a part of our journey and could rapidly accelerate our go to market strategy. We have significant demand for our product as early as 2025, so partnering with these companies to scale-up will bring our technology to market years ahead of doing it alone."

— Matthew Dawson, CEO of Elementium Materials, a battery technology with liquid electrolyte solutions

"Our pyrolysis reactor is a proprietary design that was developed during Covid. We ran simulations to prove that it works, but it was not easy to test it in a pilot facility, let alone scaling it up. We managed ... to run our pilot plant studies, while working with them remotely. We proved that our reactor worked and produced high quality products. Later, we built our own pilot plant R&D facility to continue running tests and optimizing the process. Then, there was the challenge of scaling it up to commercial size. ... We put together a task force of four different companies to come together to design and build this complex reactor in record time."

— Vibhu Sharma, CEO of InnoVentRenewables, a startup with proprietary continuous pyrolysis technology that converts waste tires, plastics, and biomass into valuable fuels and chemicals

"Energy storage and geothermal power generation are capital-intensive infrastructure projects, requiring investors with a deep commitment and the patience in terms of years to allow the technology to be developed and proven in the field. One challenge is finding that niche of investors with the vision to join our journey. We have succeeded in raising our $30 million series A with these types of investors, whom we’re confident will continue the journey as we scale."

— Cindy Taff, CEO of SageGeosystems, an energy company focused on developing and deploying advanced geothermal technologies to provide reliable power and sustainable energy storage solutions regardless of geography

"The biggest challenge we've faced has been to bring together massive independent power producers on one side who are investing hundreds of millions of dollars into grid infrastructure with multi- national tech giants on the other that don't have experience working much with energy storage. As a startup with only four employees, gaining credibility with these players was critical. We overcame this hurdle by becoming the preeminent thought leader on storage emissions, through publishing white papers, discussing the issues on podcasts, and (more)."

— Emma Konet, CTO of TierraClimate, a software provider that helps grid-scale batteries reduce carbon emissions

------

This article originally ran on EnergyCapital.